FOXP3 and cancer: Instead of applying the immunoscore, we recently reported for the first time that the combination of low CD4+ and low forkhead box P3+ (FOXP3+) T-cell densities exhibited extremely poor prognoses in terms of relapse-free survival (RFS) and cancer-specific survival (CSS) in 342 patients with stage I, II, and III CRC that had undergone curative resections [20].